HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized insights, announced it will hold a conference call on Thursday, Nov. 13, 2025, at 4:30 p.m. ET to discuss its third quarter results for the period ended Sept. 30, 2025. The company will also provide updates on regulatory progress, commercial-readiness activities, and upcoming milestones, according to a press release. A detailed press release will be issued prior to the call.
The announcement is significant as HeartBeam advances its proprietary 3D ECG technology, which received FDA clearance for arrhythmia assessment in December 2024. The company's 12-lead ECG synthesis software is currently under FDA review, and any update on this front could signal a major step toward commercial launch. The company holds over 20 issued patents related to its technology, underscoring its intellectual property moat in the portable cardiac monitoring space.
HeartBeam's platform is designed to collect ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG, all without cables. This technology aims to enable physicians to identify cardiac health trends and acute conditions outside of medical facilities, potentially redefining cardiac health management. The upcoming call will be a key opportunity for investors to gauge the company's trajectory toward commercialization and its ability to capture market share in the growing remote cardiac monitoring market.
For more details, the full press release is available at https://ibn.fm/5mXsb. Additional news and updates on HeartBeam can be found in the company's newsroom at https://ibn.fm/BEAT.
The conference call underscores HeartBeam's commitment to transparency as it navigates the regulatory pathway and prepares for potential product launch. With FDA decisions pending and commercial-readiness activities underway, the third quarter update will be closely watched by investors and industry observers alike.
